Merck

In: Finance

Sundry Photography/iStock Editorial via Getty Images Prelude Therapeutics (NASDAQ:PRLD) has forged a deal with Merck (NYSE:MRK) to test its investigational SMARCA2 degrader in combination with the latter’s blockbuster anti-PD-1 therapy, Keytruda (pembrolizumab), in patients with SMARCA4-mutated cancers. Shares of Prelude Therapeutics (PRLD) climbed as much as 28% following the news.Continue Reading

In: Finance

Sundry Photography Merck (NYSE:MRK) announced Friday that an expert panel of the EU drug regulator, the European Medicines Agency (EMA), endorsed its lung disease therapy Winrevair in combination with other medications for certain adults with pulmonary arterial hypertension (PAH). EMA’s Committee for Medicinal Products for Human Use (CHMP) issued aContinue Reading

In: Finance

Erik S. Lesser/Getty Images News Merck (NYSE:MRK) announced that a group of independent advisors to the U.S. CDC unanimously voted to recommend its newly approved pneumonia vaccine, Capvaxive, for adults aged 65 years and older. The decision comes days after the FDA approved the 21-valent conjugate vaccine for preventing invasiveContinue Reading

In: Finance

JHVEPhoto The U.S. Food and Drug Administration (FDA) has declined to approve an antibody-drug conjugate known as HER3-DXd developed by Merck (NYSE:MRK) and Daiichi Sankyo (OTCPK:DSKYF) as a late-line option for a certain type of lung cancer. The companies announced Thursday night that the agency issued a so-called complete responseContinue Reading

In: Finance

Anne Czichos Shares of Merck KGaA (OTCPK:MKGAF) (OTCPK:MKKGY) fell in European trading on Tuesday after the German drugmaker said it would discontinue a late-stage trial for its head and neck cancer therapy xevinapant as its early results indicated a potential failure. The decision comes after the study’s data monitoring committeeContinue Reading